For once, this isn’t hyperbole. Metastatic pancreatic cancer hasn’t had a meaningful new treatment in literally decades - it’s been brutal chemotherapy or slightly less brutal chemotherapy.
The new generation of KRAS inhibitors, of which daraxonrasib is just the first to make it to approval, is genuinely a practice-changing breakthrough.
It won’t cure people with metastatic disease, but it will help a lot live better lives for longer.
> For once, this isn’t hyperbole.
Am I missing something?
From other sources:
> Median overall survival: 13.2 months versus about 6.6 to 6.7 months with chemotherapy.
loading story #50593274
loading story #50593308
loading story #50593356